Saturday, 31 October 2026European Markets

EU Regulations & Policy

2 articles

EU AI Act watermarking mandate drives security research surge as vulnerabilities emerge

EU AI Act watermarking mandate drives security research surge as vulnerabilities emerge

The EU AI Act's watermarking requirements for AI-generated content are fueling increased research into attack methods, following NTT DATA's December 2025 disclosure of vulnerabilities. Security experts predict an arms race between watermarking implementation and circumvention techniques as the regulation takes effect.

ViaNews Editorial Team (Europe)•
The Monolith Problem: Why Europe's AI Governance Must Break With Big Tech's One-Size-Fits-All Model

The Monolith Problem: Why Europe's AI Governance Must Break With Big Tech's One-Size-Fits-All Model

Leading AI researchers are building a compelling case that centralised, large-scale AI development is structurally unsafe and economically exclusionary — and their arguments carry direct implications for European regulators still defining what the AI Act means in practice. At stake is whether the EU will entrench the dominance of a handful of American and Chinese technology giants, or chart a genuinely alternative path.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com